Functional images reflect aggressiveness of endometrial carcinoma: Estrogen receptor expression combined with 18F-FDG PET

Journal of Nuclear Medicine

Volumn 50, Issue 10, 2009, Pages 1598-1604

  Tsujikawa, Tetsuya ^a   Yoshida, Yoshio ^a   Kudo, Takashi ^a   Kiyono, Yasushi ^a   Kurokawa, Tetsuji ^a   Kobayashi, Masato ^a   Tsuchida, Tatsuro ^a   Fujibayashi, Yasuhisa ^a   Kotsuji, Fumikazu ^a   Okazawa, Hidehiko ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Endometrial carcinoma; Estrogen receptor; Glucose metabolism; PET; Tumor aggressiveness

Indexed keywords

ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL F 18; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG UPTAKE; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; GLUCOSE METABOLISM; HUMAN; IMAGE ANALYSIS; INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS CLASSIFICATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STANDARDIZED UPTAKE VALUE; TECHNIQUE;

ADULT; AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; ESTRADIOL; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, ESTROGEN; ROC CURVE;

EID: 70349647608     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.060145     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366:491-505.
3. Creasman WT. Announcement: FIGO stages-1988 revision. Gynecol Oncol. 1989;35:125-127.
4. Podczaski E, Kaminski P, Gurski K, et al. Detection and patterns of treatment failure in 300 consecutive cases of "early" endometrial cancer after primary surgery. Gynecol Oncol. 1992;47:323-327.
5. Carey MS, O'Connell GJ, Johanson CR, et al. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium. Gynecol Oncol. 1995;57:138-144.
6. Boronow RC, Morrow CP, Creasman WT, et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol. 1984;63:825-832. (Pubitemid 14105231)
7. Creasman WT, Morrow CP, Bundry BN, et al. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group Study. Cancer. 1987;60:2035-2041.
8. Gal D, Recio FO, Zamurovic D. The new International Federation of Gynecology and Obstetrics surgical staging and survival rates in early endometrial carcinoma. Cancer. 1992;69:200-202.
9. Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994;10:31-46.
10. Creasman WT, Kohler MF, Odicino F, et al. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol. 2004;95:593-596. (Pubitemid 39610410)
11. 18F fluorodeoxyglucose PET - initial experience. Radiology. 2008;248:599-605.
12. Kiesewetter DO, Kilbourn MR, Landvatter SW, et al. Preparation of four fluorine-18-labeled estrogen and their selective uptake in target tissue of immature rats. J Nucl Med. 1984;25:1212-1221.
13. 18F]fluorodeoxyglucose synthesizer. Nucl Med Biol. 2006;33:281-286.
14. 18F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging. 2002;29:1132-1139.
15. Saga T, Higashi T, Ishimori T, et al. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Ann Nucl Med. 2003;17:197-203. (Pubitemid 36834431)
16. Horowitz NS, Dehdashti F, Herzog TJ, et al. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol. 2004;95:546-551. (Pubitemid 39592519)
17. Chao A, Chang TC, Ng KK, et al. 18F-FDG PET in the management of endometrial cancer. Eur J Nucl Med Mol Imaging. 2006;33:36-44. (Pubitemid 41785307)
18. Grasel RP, Outwater EK, Siegelman ES, et al. Endometrial polyps: MR imaging features and distinction from endometrial carcinoma. Radiology. 2000;214:47-52. (Pubitemid 30019868)
19. Takeuchi M, Matsuzaki K, Uehara H, et al. Pathologies of the uterine endometrial cavity: usual and unusual manifestations and pitfalls on magnetic resonance imaging. Eur Radiol. 2005;15:2244-2255. (Pubitemid 41600109)
20. Mariani A, Webb MJ, Keeney GL, et al. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000;182:1506-1519.
21. Hidaka t, Kato K, Yonezawa R, et al. Omission of lymphadenectomy is possible for low-risk corpus cancer. Eur J Surg Oncol. 2007;33: 86-90.